Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study - PubMed (original) (raw)
Multicenter Study
. 1995 Nov 27;155(21):2336-40.
Affiliations
- PMID: 7487259
Multicenter Study
Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study
B M Farr et al. Arch Intern Med. 1995.
Abstract
Background: Three randomized controlled trials of the effectiveness of pneumococcal vaccine in elderly and chronically ill adults in the United States have failed to show significant protective efficacy during 44,213 person-years of follow-up. Case-control studies have greater statistical power to detect significant prevention of rare diseases such as pneumococcal bacteremia, but they also have a greater susceptibility to bias, necessitating consistent results from multiple studies. Three case-control studies at two different universities have shown prevention of systemic infection, but another study found no benefit.
Methods: Patients with pneumococcal bacteremia who were at least 2 years old and had chronic illness indicating the need for pneumococcal vaccine, or who were at least 65 years old were compared with matched control subjects for frequency of prior vaccination. Matching variables included date of admission, age, sex, race, type and duration of chronic illness serving as the major vaccine indication, number of vaccine indications and number of medical hospitalizations since licensure of the pneumococcal vaccine in 1978, and type of primary medical care.
Results: Pneumococcal vaccination was documented in the records of six (7%) of 85 cases and 26 (17%) of 152 control subjects, suggesting 81% efficacy in conditional logistical regression analysis (95% confidence interval, 34% to 94%, P = .008).
Conclusions: Four case-control studies at three universities have now demonstrated significant protective efficacy of pneumococcal vaccine for preventing pneumococcal bacteremia. The development of antibiotic-resistant Streptococcus pneumoniae indicates an urgent need for an increased rate of vaccination among high-risk patients and for the development of more immunogenic conjugate vaccines that may enhance efficacy among elderly and immunocompromised patients as well as infants.
Similar articles
- Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use.
Pilishvili T, Zell ER, Farley MM, Schaffner W, Lynfield R, Nyquist AC, Vazquez M, Bennett NM, Reingold A, Thomas A, Jackson D, Schuchat A, Whitney CG. Pilishvili T, et al. Pediatrics. 2010 Jul;126(1):e9-17. doi: 10.1542/peds.2009-2150. Epub 2010 Jun 14. Pediatrics. 2010. PMID: 20547641 - The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.
Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD. Shapiro ED, et al. N Engl J Med. 1991 Nov 21;325(21):1453-60. doi: 10.1056/NEJM199111213252101. N Engl J Med. 1991. PMID: 1944423 Clinical Trial. - Pneumococcal vaccine.
LaForce FM. LaForce FM. Semin Respir Infect. 1989 Dec;4(4):293-8. Semin Respir Infect. 1989. PMID: 2697052 Review. - Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study.
Barricarte A, Castilla J, Gil-Setas A, Torroba L, Navarro-Alonso JA, Irisarri F, Arriazu M. Barricarte A, et al. Clin Infect Dis. 2007 Jun 1;44(11):1436-41. doi: 10.1086/516779. Epub 2007 Apr 16. Clin Infect Dis. 2007. PMID: 17479939 - Pneumococcal vaccine in the prevention of community-acquired pneumonia: a skeptical view of cost-effectiveness.
Simberkoff MS. Simberkoff MS. Semin Respir Infect. 1993 Dec;8(4):294-9. Semin Respir Infect. 1993. PMID: 7938926 Review.
Cited by
- [Guidelines for the management of community pneumonia in adult who needs hospitalization].
Álvarez-Rocha L, Alós JI, Blanquer J, Álvarez-Lerma F, Garau J, Guerrero A, Torres A, Cobo J, Jordá R, Menéndez R, Olaechea P, Rodríguez de Castro F; Grupo de Estudio de la Neumonía Comunitaria Grave. Álvarez-Rocha L, et al. Med Intensiva. 2005 Feb;29(1):21-62. doi: 10.1016/S0210-5691(05)74199-1. Epub 2009 Jan 6. Med Intensiva. 2005. PMID: 38620135 Free PMC article. Spanish. - Pneumococcal Disease and the Effectiveness of the PPV23 Vaccine in Adults: A Two-Stage Bayesian Meta-Analysis of Observational and RCT Reports.
Latifi-Navid H, Latifi-Navid S, Mostafaiy B, Jamalkandi SA, Ahmadi A. Latifi-Navid H, et al. Sci Rep. 2018 Jul 23;8(1):11051. doi: 10.1038/s41598-018-29280-2. Sci Rep. 2018. PMID: 30038423 Free PMC article. - Effectiveness of 23-valent pneumococcal polysaccharide vaccination in preventing community-acquired pneumonia hospitalization and severe outcomes in the elderly in Spain.
Domínguez À, Soldevila N, Toledo D, Torner N, Force L, Pérez MJ, Martín V, Rodríguez-Rojas L, Astray J, Egurrola M, Sanz F, Castilla J; Working Group of the Project PI12/02079. Domínguez À, et al. PLoS One. 2017 Feb 10;12(2):e0171943. doi: 10.1371/journal.pone.0171943. eCollection 2017. PLoS One. 2017. PMID: 28187206 Free PMC article. - Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease.
Walters JA, Tang JN, Poole P, Wood-Baker R. Walters JA, et al. Cochrane Database Syst Rev. 2017 Jan 24;1(1):CD001390. doi: 10.1002/14651858.CD001390.pub4. Cochrane Database Syst Rev. 2017. PMID: 28116747 Free PMC article. Review. - Factors associated with pneumococcal polysaccharide vaccination of the elderly in Spain: A cross-sectional study.
Domínguez A, Soldevila N, Toledo D, Godoy P, Torner N, Force L, Castilla J, Mayoral JM, Tamames S, Martín V, Egurrola M, Sanz F, Astray J; Project Pi12/02079 Working Group. Domínguez A, et al. Hum Vaccin Immunother. 2016 Jul 2;12(7):1891-9. doi: 10.1080/21645515.2016.1149661. Epub 2016 Apr 11. Hum Vaccin Immunother. 2016. PMID: 27064311 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical